Navigation Links
Advanced Life Sciences Announces First Quarter 2008 Financial Results
Date:5/7/2008

nue studies with the National Institute of Allergy and Infectious

Diseases (NIAID) and the U.S. Army Medical Research Institute for

Infectious Diseases (USAMRIID) to explore cethromycin's activity against

high-priority bioterror agents for its use as a broad spectrum

countermeasure. Submit proposals to the Department of Defense and the

Department of Health and Human Services to fund the advanced development

of cethromycin in combating bioterror agents such as anthrax, tularemia,

plague and Burkholderia pseudomallei;

* Initiate enrollment by the end of the summer in Phase I/II

dose-escalating study to assess the safety, tolerability, and

preliminary efficacy of ALS-357 topically administered to patients with

cutaneous metastatic melanoma;

* Present cethromycin clinical data at ICAAC in the Fall.

Financial Guidance for 2008

Advanced Life Sciences expects its 2008 cash requirements excluding milestone payments that become due upon NDA filing to fall in the range of $16 million and $17 million. The first quarter cash use of $5.7 million reflects continued NDA submission costs that will curtail substantially in the coming quarters. Accordingly, we expect our quarterly cash use to decrease as we move forward with our operations. The cash used will be applied toward remaining cethromycin NDA submission activities, manufacturing costs, medical communication investments, ALS-357 clinical costs, and general operating expenses. We believe that this cash balance will be sufficient to allow us to progress into a commercial partnership which will support the ongoing funding needs of the Company.

Conference Call Details

Advanced Life Sciences will host a conference call and live webcast at 10:00 a.m. Eastern Time on Wednesday, May 7, 2008 to discuss the Company's financial results for the first quarter.

The conference call will be webcast simultaneously o
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast
2. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
3. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
4. Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements
5. Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin
6. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
7. Advanced Life Sciences Receives Nasdaq Notification
8. Advanced Life Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
11. Advanced Medical Specialties Joins US Oncology Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... has observed tiny quantum vortices in cold droplets of ... Science that the exotic vortices arrange themselves as ... first time that the quantum vortices, which have already ... as superfluid helium, have been detected in nanodroplets. "The ... of the University of Southern California, one of the ...
(Date:8/21/2014)... , Aug. 21, 2014 Telomere Biosciences, ... their Nutraceutical "TELO-20 for Dogs" with Telomerase ... supplement in the world for dogs. Telomeres are ... chromosome in the body. A wealth of ground-breaking ... in Telomere Science and Aging, including Nobel laureates, ...
(Date:8/21/2014)... YORK , Aug. 21, 2014 ... congratulates Immune Pharmaceuticals Inc., a biotechnology company, on ... Market.  Immune previously traded on OTCQX®, the best ... by OTC Markets Group. Logo - ... Pharmaceuticals on the successful execution of its growth ...
(Date:8/21/2014)... Ontotext S4 , The Self ... . Now the same enterprise hardened text mining, ... unstructured data is available to start-ups and mid-size businesses ... Organizations that do not have resources to evaluate and ... S4 since there is no need for on premise ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
... Shionogi-ViiV Healthcare, LLC announced today that the first ... designed to support a new fixed-dose combination (FDC) ... investigational regimen, known as 572-Trii, will combine the ... combination nucleoside reverse transcriptase inhibitor (NRTI) Kivexa®/Epzicom® (ABC/3TC). ...
... TRIANGLE PARK, N.C., Feb. 2, 2011 The day ... off the shelf for use in life-saving vascular surgeries ... published in the current issue of the journal, ... vascular grafts (TEVGs) that are immediately-available at the time ...
... Inc. (Nasdaq: SGMO ) today reported fourth quarter ... For the fourth quarter ended December 31, 2010, Sangamo ... per share, compared to a net loss of $2.4  million, ... As of December 31, 2010, the company had cash, cash ...
Cached Biology Technology:Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 2Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 3Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 4Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 5Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 6Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 7Bioengineered veins offer new hope on horizon for patients lacking healthy veins for coronary bypass surgery or dialysis 2Bioengineered veins offer new hope on horizon for patients lacking healthy veins for coronary bypass surgery or dialysis 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 7
(Date:8/21/2014)... team has successfully replicated one of the crucial steps ... by sunlight which could manufacture hydrogen as a fuel. ... is an exciting prospect to use them to create ... Kastoori Hingorani, from the ARC Centre of Excellence for ... , Hydrogen offers potential as a zero-carbon replacement for ...
(Date:8/20/2014)... Cancer Institute (HCI) at the University of Utah have ... encodes BCR-ABL, the unregulated enzyme driving the blood cancer ... Society, nearly 6,000 new cases of CML will be ... tyrosine kinase inhibitors (TKIs), target BCR-ABL and are effective ... but control it in a way that allows patients ...
(Date:8/20/2014)... population-based screening outcomes of approximately 3 million infants, a ... at the University of Massachusetts Medical School, have shown ... be successfully implemented across public health newborn screening programs. ... Aug. 20 issue of the Journal of the ... rate of SCID in newborns is higher than previously ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2Blueprint for next generation of chronic myeloid leukemia treatment 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
... the Faculty of Veterinary Medicine at Universitat Autnoma ... Research in Agricultural Genomics (CRAG), the Centre for ... for Agrarian Technology and Research in Madrid and ... the first partial genome sequencing of an Iberian ...
... The debate surrounding carbon capture and storage intensifies as ... Berkeley National Laboratory (Berkeley Lab) examine the capacity for ... in the new journal Greenhouse Gases: Science & ... the conclusions drawn in an earlier study by Ehlig-Economides ...
... biochemistry is how proteins recognize "correct" interaction partners in ... critical to know than in the brain, where interactions ... A team of biologists at the Salk Institute for ... regulates availability of a brain channel that modulates neuronal ...
Cached Biology News:First partial sequencing of an Iberian pig 2Carbon capture and storage: Carbon dioxide pressure dissipates in underground reservoirs 2Salk scientists crack molecular code regulating neuronal excitability 2Salk scientists crack molecular code regulating neuronal excitability 3
...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... work area that will help protect your ... irradiate the work area prior to use, ... be amplified. Containment features reduce the chance ... acrylic windows for a clear view, an ...
... Have you bought a Perkin Elmer UltraVIEW system ... the Andor iXon and iQ software? No problem. ... upgrade. You keep your existing microscope, lasers, Sutter ... customise it to work with our precision controller ...
Biology Products: